Does the media prefer VRTX or AMZN?

In the previous week, Amazon.com had 183 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 245 mentions for Amazon.com and 62 mentions for Vertex Pharmaceuticals. Amazon.com's average media sentiment score of 0.86 beat Vertex Pharmaceuticals' score of 0.76 indicating that Amazon.com is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 31 Very Positive mention(s) 9 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Amazon.com 143 Very Positive mention(s) 32 Positive mention(s) 37 Neutral mention(s) 20 Negative mention(s) 12 Very Negative mention(s) Positive

Does the media favor VRTX or AXSM?

In the previous week, Vertex Pharmaceuticals had 48 more articles in the media than Axsome Therapeutics. MarketBeat recorded 62 mentions for Vertex Pharmaceuticals and 14 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.84 beat Vertex Pharmaceuticals' score of 0.76 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 31 Very Positive mention(s) 9 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 6 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor CRSP or VRTX?

In the previous week, Vertex Pharmaceuticals had 49 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 62 mentions for Vertex Pharmaceuticals and 13 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 0.76 beat CRISPR Therapeutics' score of 0.64 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CRISPR Therapeutics 3 Very Positive mention(s) 3 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 31 Very Positive mention(s) 9 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation and earnings, VRTX or GOOG?

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vertex Pharmaceuticals $12.00B 10.26 $3.95B $16.86 28.79 Alphabet $402.84B 10.68 $132.17B $13.11 27.08

Does the media prefer VRTX or GOOG?

In the previous week, Alphabet had 69 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 131 mentions for Alphabet and 62 mentions for Vertex Pharmaceuticals. Alphabet's average media sentiment score of 0.94 beat Vertex Pharmaceuticals' score of 0.76 indicating that Alphabet is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vertex Pharmaceuticals 31 Very Positive mention(s) 9 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Alphabet 86 Very Positive mention(s) 6 Positive mention(s) 26 Neutral mention(s) 8 Negative mention(s) 3 Very Negative mention(s) Positive

Does the media refer more to ISRG or VRTX?

In the previous week, Vertex Pharmaceuticals had 32 more articles in the media than Intuitive Surgical. MarketBeat recorded 62 mentions for Vertex Pharmaceuticals and 30 mentions for Intuitive Surgical. Intuitive Surgical's average media sentiment score of 1.02 beat Vertex Pharmaceuticals' score of 0.76 indicating that Intuitive Surgical is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Intuitive Surgical 18 Very Positive mention(s) 3 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Vertex Pharmaceuticals 31 Very Positive mention(s) 9 Positive mention(s) 19 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Vertex Pharmaceuticals (VRTX) Competitors

$485.39 -11.11 (-2.24%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$487.88 +2.49 (+0.51%)

As of 07/10/2026 07:54 PM Eastern

Compare

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

Should you buy Vertex Pharmaceuticals stock or one of its competitors? MarketBeat compares Vertex Pharmaceuticals with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Vertex Pharmaceuticals include Amazon.com (AMZN), Axsome Therapeutics (AXSM), CRISPR Therapeutics (CRSP), Alphabet (GOOG), and Intuitive Surgical (ISRG).

How does Vertex Pharmaceuticals compare to Amazon.com?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Amazon.com (NASDAQ:AMZN) are related large-cap companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, media sentiment, profitability and analyst recommendations.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Amazon.com's net margin of 12.22%. Vertex Pharmaceuticals' return on equity of 23.86% beat Amazon.com's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Amazon.com	12.22%	19.92%	9.86%

Amazon.com has higher revenue and earnings than Vertex Pharmaceuticals. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Amazon.com, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.26	$3.95B	$16.86	28.79
Amazon.com	$716.92B	3.68	$77.67B	$8.36	29.35

Vertex Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Amazon.com has a beta of 1.46, suggesting that its share price is 46% more volatile than the broader market.

Vertex Pharmaceuticals currently has a consensus price target of $557.09, suggesting a potential upside of 14.77%. Amazon.com has a consensus price target of $312.79, suggesting a potential upside of 27.49%. Given Amazon.com's stronger consensus rating and higher possible upside, analysts plainly believe Amazon.com is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.84
Amazon.com	0 Sell rating(s)	3 Hold rating(s)	57 Buy rating(s)	0 Strong Buy rating(s)	2.95

In the previous week, Amazon.com had 183 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 245 mentions for Amazon.com and 62 mentions for Vertex Pharmaceuticals. Amazon.com's average media sentiment score of 0.86 beat Vertex Pharmaceuticals' score of 0.76 indicating that Amazon.com is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	31 Very Positive mention(s)	9 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Amazon.com	143 Very Positive mention(s)	32 Positive mention(s)	37 Neutral mention(s)	20 Negative mention(s)	12 Very Negative mention(s)	Positive

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 72.2% of Amazon.com shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 8.9% of Amazon.com shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Amazon.com beats Vertex Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Axsome Therapeutics (NASDAQ:AXSM) are both large-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, earnings, profitability, dividends, risk, institutional ownership, media sentiment and analyst recommendations.

Vertex Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market. Comparatively, Axsome Therapeutics has a beta of 0.6, indicating that its share price is 40% less volatile than the broader market.

In the previous week, Vertex Pharmaceuticals had 48 more articles in the media than Axsome Therapeutics. MarketBeat recorded 62 mentions for Vertex Pharmaceuticals and 14 mentions for Axsome Therapeutics. Axsome Therapeutics' average media sentiment score of 0.84 beat Vertex Pharmaceuticals' score of 0.76 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	31 Very Positive mention(s)	9 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	6 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 81.5% of Axsome Therapeutics shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by company insiders. Comparatively, 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Vertex Pharmaceuticals has a net margin of 35.51% compared to Axsome Therapeutics' net margin of -26.59%. Vertex Pharmaceuticals' return on equity of 23.86% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Vertex Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.26	$3.95B	$16.86	28.79
Axsome Therapeutics	$638.50M	18.84	-$183.17M	-$3.73	N/A

Vertex Pharmaceuticals presently has a consensus price target of $557.09, indicating a potential upside of 14.77%. Axsome Therapeutics has a consensus price target of $259.05, indicating a potential upside of 10.80%. Given Vertex Pharmaceuticals' higher probable upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.84
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

Summary

Vertex Pharmaceuticals beats Axsome Therapeutics on 11 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

CRISPR Therapeutics (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their dividends, media sentiment, valuation, profitability, earnings, risk, institutional ownership and analyst recommendations.

CRISPR Therapeutics currently has a consensus target price of $67.78, indicating a potential upside of 27.04%. Vertex Pharmaceuticals has a consensus target price of $557.09, indicating a potential upside of 14.77%. Given CRISPR Therapeutics' higher possible upside, equities analysts clearly believe CRISPR Therapeutics is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
CRISPR Therapeutics	1 Sell rating(s)	7 Hold rating(s)	10 Buy rating(s)	1 Strong Buy rating(s)	2.58
Vertex Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.84

CRISPR Therapeutics has a beta of 1.71, indicating that its share price is 71% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

Vertex Pharmaceuticals has a net margin of 35.51% compared to CRISPR Therapeutics' net margin of -13,856.54%. Vertex Pharmaceuticals' return on equity of 23.86% beat CRISPR Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
CRISPR Therapeutics	-13,856.54%	-25.66%	-20.39%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Vertex Pharmaceuticals has higher revenue and earnings than CRISPR Therapeutics. CRISPR Therapeutics is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
CRISPR Therapeutics	$3.51M	1,465.99	-$581.60M	-$6.22	N/A
Vertex Pharmaceuticals	$12.00B	10.26	$3.95B	$16.86	28.79

69.2% of CRISPR Therapeutics shares are owned by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. 4.3% of CRISPR Therapeutics shares are owned by insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Vertex Pharmaceuticals had 49 more articles in the media than CRISPR Therapeutics. MarketBeat recorded 62 mentions for Vertex Pharmaceuticals and 13 mentions for CRISPR Therapeutics. Vertex Pharmaceuticals' average media sentiment score of 0.76 beat CRISPR Therapeutics' score of 0.64 indicating that Vertex Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
CRISPR Therapeutics	3 Very Positive mention(s)	3 Positive mention(s)	3 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	31 Very Positive mention(s)	9 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats CRISPR Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Alphabet?

Vertex Pharmaceuticals (NASDAQ:VRTX) and Alphabet (NASDAQ:GOOG) are related large-cap companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, media sentiment, valuation, earnings, analyst recommendations, dividends, institutional ownership and risk.

Alphabet has higher revenue and earnings than Vertex Pharmaceuticals. Alphabet is trading at a lower price-to-earnings ratio than Vertex Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vertex Pharmaceuticals	$12.00B	10.26	$3.95B	$16.86	28.79
Alphabet	$402.84B	10.68	$132.17B	$13.11	27.08

Alphabet has a net margin of 37.92% compared to Vertex Pharmaceuticals' net margin of 35.51%. Alphabet's return on equity of 38.99% beat Vertex Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vertex Pharmaceuticals	35.51%	23.86%	17.13%
Alphabet	37.92%	38.99%	27.41%

91.0% of Vertex Pharmaceuticals shares are owned by institutional investors. Comparatively, 27.3% of Alphabet shares are owned by institutional investors. 0.2% of Vertex Pharmaceuticals shares are owned by insiders. Comparatively, 13.0% of Alphabet shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Vertex Pharmaceuticals currently has a consensus target price of $557.09, indicating a potential upside of 14.77%. Alphabet has a consensus target price of $378.53, indicating a potential upside of 6.62%. Given Vertex Pharmaceuticals' higher possible upside, analysts clearly believe Vertex Pharmaceuticals is more favorable than Alphabet.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vertex Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.84
Alphabet	0 Sell rating(s)	4 Hold rating(s)	27 Buy rating(s)	5 Strong Buy rating(s)	3.03

In the previous week, Alphabet had 69 more articles in the media than Vertex Pharmaceuticals. MarketBeat recorded 131 mentions for Alphabet and 62 mentions for Vertex Pharmaceuticals. Alphabet's average media sentiment score of 0.94 beat Vertex Pharmaceuticals' score of 0.76 indicating that Alphabet is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vertex Pharmaceuticals	31 Very Positive mention(s)	9 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Alphabet	86 Very Positive mention(s)	6 Positive mention(s)	26 Neutral mention(s)	8 Negative mention(s)	3 Very Negative mention(s)	Positive

Vertex Pharmaceuticals has a beta of 0.29, suggesting that its share price is 71% less volatile than the broader market. Comparatively, Alphabet has a beta of 1.23, suggesting that its share price is 23% more volatile than the broader market.

Summary

Alphabet beats Vertex Pharmaceuticals on 13 of the 17 factors compared between the two stocks.

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Intuitive Surgical (NASDAQ:ISRG) and Vertex Pharmaceuticals (NASDAQ:VRTX) are both large-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, earnings and profitability.

Vertex Pharmaceuticals has higher revenue and earnings than Intuitive Surgical. Vertex Pharmaceuticals is trading at a lower price-to-earnings ratio than Intuitive Surgical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Intuitive Surgical	$10.06B	14.31	$2.86B	$8.25	49.31
Vertex Pharmaceuticals	$12.00B	10.26	$3.95B	$16.86	28.79

Vertex Pharmaceuticals has a net margin of 35.51% compared to Intuitive Surgical's net margin of 28.15%. Vertex Pharmaceuticals' return on equity of 23.86% beat Intuitive Surgical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Intuitive Surgical	28.15%	15.98%	14.07%
Vertex Pharmaceuticals	35.51%	23.86%	17.13%

Intuitive Surgical currently has a consensus price target of $569.20, suggesting a potential upside of 39.93%. Vertex Pharmaceuticals has a consensus price target of $557.09, suggesting a potential upside of 14.77%. Given Intuitive Surgical's higher probable upside, research analysts plainly believe Intuitive Surgical is more favorable than Vertex Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Intuitive Surgical	1 Sell rating(s)	7 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.71
Vertex Pharmaceuticals	0 Sell rating(s)	4 Hold rating(s)	21 Buy rating(s)	0 Strong Buy rating(s)	2.84

83.6% of Intuitive Surgical shares are held by institutional investors. Comparatively, 91.0% of Vertex Pharmaceuticals shares are held by institutional investors. 0.6% of Intuitive Surgical shares are held by company insiders. Comparatively, 0.2% of Vertex Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Intuitive Surgical has a beta of 1.46, indicating that its share price is 46% more volatile than the broader market. Comparatively, Vertex Pharmaceuticals has a beta of 0.29, indicating that its share price is 71% less volatile than the broader market.

In the previous week, Vertex Pharmaceuticals had 32 more articles in the media than Intuitive Surgical. MarketBeat recorded 62 mentions for Vertex Pharmaceuticals and 30 mentions for Intuitive Surgical. Intuitive Surgical's average media sentiment score of 1.02 beat Vertex Pharmaceuticals' score of 0.76 indicating that Intuitive Surgical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Intuitive Surgical	18 Very Positive mention(s)	3 Positive mention(s)	7 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Vertex Pharmaceuticals	31 Very Positive mention(s)	9 Positive mention(s)	19 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vertex Pharmaceuticals beats Intuitive Surgical on 10 of the 17 factors compared between the two stocks.

Get Vertex Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding VRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

VRTX vs. The Competition

Export

Metric	Vertex Pharmaceuticals	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$126.01B	$3.79B	$7.12B	$12.61B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	28.79	21.27	27.22	24.56
Price / Sales	10.26	323.90	590.16	121.71
Price / Cash	28.25	147.64	49.34	60.04
Price / Book	6.60	8.41	10.90	6.39
Net Income	$3.95B	$23.85M	$3.57B	$331.44M
7 Day Performance	-8.08%	-0.76%	-0.25%	0.37%
1 Month Performance	9.07%	11.35%	5.77%	2.17%
1 Year Performance	3.53%	51.68%	28.14%	20.90%

Vertex Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
VRTX Vertex Pharmaceuticals	4.0434 of 5 stars	$485.39 -2.2%	$557.09 +14.8%	+1.2%	$126.01B	$12.00B	28.79	6,400	Trending News Analyst Forecast Insider Trade
AMZN Amazon.com	4.8489 of 5 stars	$244.16 +0.6%	$312.79 +28.1%	+10.4%	$2.63T	$742.78B	29.21	1,576,000	Trending News Analyst Forecast
AXSM Axsome Therapeutics	3.6691 of 5 stars	$242.60 -0.7%	$258.95 +6.7%	+111.1%	$12.48B	$638.50M	N/A	380	News Coverage Analyst Forecast
CRSP CRISPR Therapeutics	3.7183 of 5 stars	$61.89 +3.0%	$67.78 +9.5%	-9.6%	$5.97B	$3.51M	N/A	460	Analyst Forecast
GOOG Alphabet	4.077 of 5 stars	$364.90 +2.4%	$376.19 +3.1%	+98.7%	$4.42T	$402.84B	27.83	190,200	Trending News Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:VRTX) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

How does Vertex Pharmaceuticals compare to Amazon.com?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Summary

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Vertex Pharmaceuticals (VRTX) Competitors

VRTX vs. AMZN, AXSM, CRSP, GOOG, and ISRG

How does Vertex Pharmaceuticals compare to Amazon.com?

Is VRTX or AMZN more profitable?

Which has better valuation & earnings, VRTX or AMZN?

Which has more risk & volatility, VRTX or AMZN?

Do analysts prefer VRTX or AMZN?

Does the media prefer VRTX or AMZN?

Do institutionals and insiders hold more shares of VRTX or AMZN?

Summary

How does Vertex Pharmaceuticals compare to Axsome Therapeutics?

Which has more volatility and risk, VRTX or AXSM?

Does the media favor VRTX or AXSM?

Do institutionals and insiders have more ownership in VRTX or AXSM?

Is VRTX or AXSM more profitable?

Which has stronger earnings and valuation, VRTX or AXSM?

Do analysts rate VRTX or AXSM?

Summary

How does Vertex Pharmaceuticals compare to CRISPR Therapeutics?

Do analysts rate CRSP or VRTX?

Which has more risk & volatility, CRSP or VRTX?

Is CRSP or VRTX more profitable?

Which has higher valuation and earnings, CRSP or VRTX?

Do insiders and institutionals have more ownership in CRSP or VRTX?

Does the media favor CRSP or VRTX?

Summary

How does Vertex Pharmaceuticals compare to Alphabet?

Which has better valuation and earnings, VRTX or GOOG?

Is VRTX or GOOG more profitable?

Do insiders & institutionals believe in VRTX or GOOG?

Do analysts rate VRTX or GOOG?

Does the media prefer VRTX or GOOG?

Which has more risk and volatility, VRTX or GOOG?

Summary

How does Vertex Pharmaceuticals compare to Intuitive Surgical?

Which has stronger earnings & valuation, ISRG or VRTX?

Is ISRG or VRTX more profitable?

Do analysts recommend ISRG or VRTX?

Do insiders and institutionals believe in ISRG or VRTX?

Which has more risk & volatility, ISRG or VRTX?

Does the media refer more to ISRG or VRTX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

VRTX vs. The Competition

Vertex Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools